Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of SHP2 as an approach to block RAS-driven cancers.

Advances in cancer research - 1 Jan 2022

Chou Yu-Ting, Bivona Trever G

Abstract excerpt

The non-receptor protein tyrosine phosphatase SHP2 (encoded by PTPN11) is a critical component of RAS/MAPK signaling by acting upstream of RAS to promote oncogenic signaling and tumor growth. Over three decades, SHP2 was considered "undruggable" because enzymatic active-site inhibitors generally showed off-target inhibition of other proteins and low membrane permeability. More recently, allosteric SHP2 inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Receptor Protein-Tyrosine Kinases
Share to Signal Transduction
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to ras Proteins

Source

Identifiers

PMID: 35101231
DOI: 10.1016/bs.acr.2021.07.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of SHP2 as an approach to block RAS-driven cancers.PMID 35101231Read ↗

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.Semantic proximity Read ↗

Strategies to overcome drug resistance using SHP2 inhibitorsSemantic proximity Read ↗

Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancersSemantic proximity Read ↗

PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.Semantic proximity Read ↗

Targeting SHP2 phosphatase in hematological malignancies.Semantic proximity Read ↗

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.Semantic proximity Read ↗

Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.Semantic proximity Read ↗

RAS, wanted dead or alive: Advances in targeting RAS mutant cancers.Semantic proximity Read ↗

Targeted degradation of the oncogenic phosphatase SHP2Semantic proximity Read ↗

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.Semantic proximity Read ↗

JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.Semantic proximity Read ↗

Targeted Degradation of the Oncogenic Phosphatase SHP2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.